Table 2.

Pharmacokinetic parameters of sorafenib in rats after oral administration of sorafenib with or without PCN.

Parameters	(-) PCN treatment	(+) PCN treatment
Kα (h−1)	0.98 ± 0.17	0.79 ± 0.11
α (h−1)	0.67 ± 0.15	0.78 ± 0.14
β (h−1)	0.026 ± 0.013	0.016 ± 0.003
Tka (h)	0.69 ± 0.15	0.88 ± 1.12
Tα (h)	1.03 ± 0.35	0.89 ± 0.16
Tβ (h)	27.07 ± 4.38	47.72 ± 4.61∗
AUC (μg/mL/h)	125.55 ± 11.11	217.26 ± 26.42∗

(+) PCN treatment: sorafenib (50 mg/kg) was administered orally with PCN treatment (75 mg/kg); (-) PCN treatment: sorafenib (50 mg/kg) was administered orally without PCN treatment (75 mg/kg); Kα (h⁻¹): absorption rate constant; α (h⁻¹): distribution rate constant; β (h⁻¹): elimination rate constant; Tka (h): absorption half-life; Tα: distribution half-life; Tβ (h): elimination half-life; AUC (μg/mL/h): area under concentration-time curve. (^∗P < 0.05 compared with (-) PCN treatment).